EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hypertension associated with systemic therapy for hepatocellular carcinoma and management strategies

Yuqing Li, Boxuan Wang, Dan Zhang, Ying Xin, Xingyu Wang

Frontiers in Pharmacology · 14.05.2026 · 17

DOI: 10.3389/fphar.2026.1780200 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.05.2026. Verfasst von Yuqing Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: The People's Hospital of Qionghai City, Qionghai, China. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiangiogenic therapy and immune checkpoint inhibitors represent two cornerstone approaches in the current systemic treatment of patients with hepatocellular carcinoma (HCC). Since the advent of the immunotherapy era, the survival of patients with HCC, particularly those with unresectable disease, has improved significantly. However, both drug classes carry the potential for vascular injury, with hypertension being a notable adverse event. Antiangiogenic agents, such as lenvatinib and bevacizumab, frequently induce hypertension. Given that the main systemic regimens for HCC often combine multiple agents prone to cause hypertension, effective management of blood pressure is crucial for long-term adherence to cancer treatment and survival. However, patients with HCC often present with underlying conditions such as cirrhosis, portal hypertension, and ascites. These conditions themselves or their treatments, such as diuretics and non-selective beta-blockers, may lower blood pressure, which is often accompanied by hypoperfusion of vital abdominal organs, particularly the kidneys, posing greater harm than hypertension alone. Consequently, blood pressure management in patients undergoing systemic HCC therapy is highly complex, necessitating the involvement of a ultidisciplinary team collaboration in future practice.

Schlagwörter

Stichwörter der Autor:innen

antiangiogenic therapybevacizumabcancer therapy-related hypertensionhepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapytyrosine kinase inhibitors

Autor:innen und Institutionen

  • The People's Hospital of Qionghai City, Qionghai, China.
  • China-Japan Union Hospital of Jilin University, Changchun, China.
  • The First Hospital of Jilin University, Changchun, China.
  • Huancheng Township Health Center Hospital, Yushu, China.
  • Shenyang Institute of Engineering, Shenyang, China.

Zitieren

APA

Li, Y., Wang, B., Zhang, D., Xin, Y., & Wang, X. (2026). Hypertension associated with systemic therapy for hepatocellular carcinoma and management strategies. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1780200

Vancouver

Li Y, Wang B, Zhang D, Xin Y, Wang X. Hypertension associated with systemic therapy for hepatocellular carcinoma and management strategies. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1780200

BibTeX
@article{Li2026,
  author = {Li, Yuqing and Wang, Boxuan and Zhang, Dan and Xin, Ying and Wang, Xingyu},
  title = {Hypertension associated with systemic therapy for hepatocellular carcinoma and management strategies},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1780200}
}
Kostenlos starten →